Tempus AI to acquire Personalis for $1.5 billion in all-stock deal

Tempus AI agreed to acquire Personalis for about $1.5 billion, adding an ultrasensitive cancer monitoring test to the company's AI-enabled precision medicine portfolio as the minimal residual disease market expands.

"MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs," said Eric Lefkofsky, CEO of Tempus.

Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's close and a 28% premium to the 30-day volume-weighted average price. The consideration is structured as 100% stock, with Tempus holding the option to elect cash payment for up to 50% of the total. Personalis delivered preliminary second-quarter revenue of $22.4 million and 10,384 clinical tests, a 33% increase in test volumes quarter over quarter.

The deal builds on a partnership established in November 2023, under which Tempus commercialized Personalis' NeXT Personal test. With about 2.1 million new cancer diagnoses expected in the U.S. this year and Medicare coverage secured in three indications, the combined platform aims to capture a growing share of the MRD monitoring market. The transaction is expected to close in late 2026 or early 2027, subject to Personalis shareholder approval and regulatory clearances.

The acquisition brings together Tempus' multimodal data platform and AI capabilities with Personalis' tumor-informed MRD technology, which detects microscopic traces of circulating tumor DNA in a patient's blood to track treatment response and identify early recurrence. Tempus shares fell 4% in premarket trading Monday, while Personalis shares declined 5%.

"We believe this transaction represents an exciting next chapter for Personalis," said Chris Hall, CEO of Personalis. "Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners."

The MRD testing market has drawn increasing interest from diagnostics companies and health systems as longer survival rates for cancer patients create sustained demand for post-treatment monitoring. Tempus, which went public in 2024, has expanded its oncology portfolio through both organic development and strategic acquisitions, leveraging its library of multimodal clinical data to train AI models for treatment selection and drug discovery.

This article is for informational purposes only and does not constitute investment advice.